Verastem, Inc. (NASDAQ:VSTM), a biopharmaceutical company focused on discovering and developing drugs to treat breast and other cancers by targeting cancer stem cells, today announced that the underwriters of its initial public offering have exercised in full their over-allotment option for the purchase of an additional 825,000 shares of common stock at the initial public offering price of $10.00 per share, less underwriting discounts and commissions.
UBS Investment Bank and Leerink Swann LLC acted as joint book-running managers for the offering. Lazard Capital Markets LLC, Oppenheimer & Co. Inc. and Rodman & Renshaw, LLC acted as co-managers for the offering.
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on January 26, 2012.
Copies of the final prospectus relating to this offering may be obtained by contacting UBS Investment Bank, Attention: Prospectus Department, 299 Park Avenue, New York, NY 10171, (888) 827-7275, or Leerink Swann LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, (800) 808-7525, ext. 4814.Business Wire
Last updated on: 02/02/2012
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.